Spots Global Cancer Trial Database for recurrent thyroid gland carcinoma

Every month we try and update this database with for recurrent thyroid gland carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer	NCT04759911	Malignant Thyro... Poorly Differen... Recurrent Thyro... Thyroid Gland A... Thyroid Gland M... Thyroid Gland P... Thyroid Gland S...	Quality-of-Life... Questionnaire A... Selpercatinib Therapeutic Con...	12 Years -	M.D. Anderson Cancer Center
Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer	NCT02393690	Metastatic Thyr... Poorly Differen... Recurrent Thyro... Stage IV Thyroi... Stage IV Thyroi... Stage IVA Thyro... Stage IVA Thyro... Stage IVB Thyro... Stage IVB Thyro... Stage IVC Thyro... Stage IVC Thyro...	Iodine I-131 Placebo Adminis... Selumetinib	18 Years -	Academic and Community Cancer Research United
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors	NCT01709435	Recurrent Malig... Recurrent Melan... Recurrent Prima... Recurrent Thyro... Refractory Mali... Refractory Prim... Thyroid Gland M...	Cabozantinib S-... Laboratory Biom... Pharmacological...	2 Years - 18 Years	National Cancer Institute (NCI)
Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy	NCT00729157	Recurrent Thyro... Stage III Thyro... Stage III Thyro... Stage IV Thyroi... Stage IV Thyroi...	Fludeoxyglucose... Laboratory Biom... Pharmacological... Positron Emissi... Ziv-Aflibercept	18 Years -	National Cancer Institute (NCI)
Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery	NCT00381641	Differentiated ... Recurrent Thyro... Refractory Thyr... Stage III Thyro... Stage III Thyro... Stage IV Thyroi... Stage IV Thyroi... Stage IV Thyroi... Stage IVA Thyro... Stage IVA Thyro... Stage IVA Thyro... Stage IVB Thyro... Stage IVB Thyro... Stage IVB Thyro... Stage IVC Thyro... Stage IVC Thyro... Stage IVC Thyro... Thyroid Gland O... Unresectable Th...	Laboratory Biom... Pharmacogenomic... Sunitinib Sunitinib Malat...	18 Years -	National Cancer Institute (NCI)
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial	NCT04284774	Malignant Solid... Recurrent Adren... Recurrent Ectom... Recurrent Epend... Recurrent Ewing... Recurrent Hepat... Recurrent Kidne... Recurrent Lange... Recurrent Malig... Recurrent Malig... Recurrent Medul... Recurrent Melan... Recurrent Neuro... Recurrent Non-H... Recurrent Osteo... Recurrent Perip... Recurrent Rhabd... Recurrent Rhabd... Recurrent Rhabd... Recurrent Soft ... Recurrent Thyro... Recurrent WHO G... Refractory Adre... Refractory Epen... Refractory Ewin... Refractory Hepa... Refractory Lang... Refractory Mali... Refractory Mali... Refractory Medu... Refractory Mela... Refractory Neur... Refractory Non-... Refractory Oste... Refractory Peri... Refractory Rhab... Refractory Rhab... Refractory Rhab... Refractory Soft... Refractory Thyr... Refractory WHO ...	Biospecimen Col... Bone Marrow Asp... Computed Tomogr... Magnetic Resona... Positron Emissi... Radionuclide Im... Tipifarnib	12 Months - 21 Years	National Cancer Institute (NCI)
Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer	NCT02393690	Metastatic Thyr... Poorly Differen... Recurrent Thyro... Stage IV Thyroi... Stage IV Thyroi... Stage IVA Thyro... Stage IVA Thyro... Stage IVB Thyro... Stage IVB Thyro... Stage IVC Thyro... Stage IVC Thyro...	Iodine I-131 Placebo Adminis... Selumetinib	18 Years -	Academic and Community Cancer Research United
Radiofrequency Ablation for the Treatment of Benign or Low Risk Thyroid Nodule	NCT05003856	Benign Thyroid ... Recurrent Thyro... Thyroid Gland F... Thyroid Gland N... Thyroid Gland P...	Quality-of-Life... Radiofrequency ...	18 Years -	M.D. Anderson Cancer Center
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	NCT02465060	Advanced Lympho... Advanced Malign... Bladder Carcino... Breast Carcinom... Cervical Carcin... Colon Carcinoma Colorectal Carc... Endometrial Car... Esophageal Carc... Gastric Carcino... Glioma Head and Neck C... Hematopoietic a... Kidney Carcinom... Liver Carcinoma Lung Carcinoma Lymphoma Malignant Uteri... Melanoma Multiple Myelom... Ovarian Carcino... Pancreatic Carc... Prostate Carcin... Rectal Carcinom... Recurrent Bladd... Recurrent Breas... Recurrent Cervi... Recurrent Colon... Recurrent Color... Recurrent Esoph... Recurrent Gastr... Recurrent Gliom... Recurrent Head ... Recurrent Liver... Recurrent Lung ... Recurrent Lymph... Recurrent Malig... Recurrent Melan... Recurrent Multi... Recurrent Ovari... Recurrent Pancr... Recurrent Prost... Recurrent Recta... Recurrent Skin ... Recurrent Thyro... Recurrent Uteri... Refractory Lymp... Refractory Mali... Refractory Mult... Skin Carcinoma Thyroid Gland C... Uterine Corpus ...	Adavosertib Afatinib Afatinib Dimale... Binimetinib Biopsy Biospecimen Col... Capivasertib Computed Tomogr... Copanlisib Copanlisib Hydr... Crizotinib Cytology Specim... Dabrafenib Dabrafenib Mesy... Dasatinib Defactinib Defactinib Hydr... Echocardiograph... Erdafitinib Fexagratinib Ipatasertib Laboratory Biom... Larotrectinib Larotrectinib S... Magnetic Resona... Multigated Acqu... Nivolumab Osimertinib Palbociclib Pertuzumab PI3K-beta Inhib... Radiologic Exam... Radionuclide Im... Relatlimab Sapanisertib Sunitinib Malat... Taselisib Trametinib Trastuzumab Trastuzumab Emt... Ulixertinib Vismodegib	18 Years -	National Cancer Institute (NCI)
Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy	NCT00729157	Recurrent Thyro... Stage III Thyro... Stage III Thyro... Stage IV Thyroi... Stage IV Thyroi...	Fludeoxyglucose... Laboratory Biom... Pharmacological... Positron Emissi... Ziv-Aflibercept	18 Years -	National Cancer Institute (NCI)
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors	NCT01709435	Recurrent Malig... Recurrent Melan... Recurrent Prima... Recurrent Thyro... Refractory Mali... Refractory Prim... Thyroid Gland M...	Cabozantinib S-... Laboratory Biom... Pharmacological...	2 Years - 18 Years	National Cancer Institute (NCI)
Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer	NCT00625846	Recurrent Thyro... Stage III Diffe... Stage III Thyro... Stage IVA Diffe... Stage IVA Thyro... Stage IVA Thyro... Stage IVB Diffe... Stage IVB Thyro... Stage IVB Thyro... Stage IVC Diffe... Stage IVC Thyro... Stage IVC Thyro... Thyroid Gland A...	Laboratory Biom... Pazopanib Hydro...	19 Years -	National Cancer Institute (NCI)
Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer	NCT01811212	Poorly Differen... Recurrent Thyro... Stage I Thyroid... Stage I Thyroid... Stage II Thyroi... Stage II Thyroi... Stage III Thyro... Stage III Thyro... Stage IVA Thyro... Stage IVA Thyro... Stage IVB Thyro... Stage IVB Thyro... Stage IVC Thyro... Stage IVC Thyro... Tall Cell Varia... Thyroid Gland O...	Cabozantinib S-... Laboratory Biom...	18 Years -	National Cancer Institute (NCI)
Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine	NCT00559949	Recurrent Thyro... Stage I Thyroid... Stage II Thyroi... Stage III Thyro... Stage IV Thyroi...	Laboratory Biom... Selumetinib	18 Years -	National Cancer Institute (NCI)
Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer	NCT04759911	Malignant Thyro... Poorly Differen... Recurrent Thyro... Thyroid Gland A... Thyroid Gland M... Thyroid Gland P... Thyroid Gland S...	Quality-of-Life... Questionnaire A... Selpercatinib Therapeutic Con...	12 Years -	M.D. Anderson Cancer Center
Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine	NCT00559949	Recurrent Thyro... Stage I Thyroid... Stage II Thyroi... Stage III Thyro... Stage IV Thyroi...	Laboratory Biom... Selumetinib	18 Years -	National Cancer Institute (NCI)

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: